Shares of Kadmon Holdings Inc (NYSE:KDMN) have earned an average recommendation of “Hold” from the six ratings firms that are currently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $9.75.
Several research firms recently commented on KDMN. Zacks Investment Research downgraded Kadmon from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Kadmon in a report on Friday, December 15th. Finally, WBB Securities cut Kadmon from a “hold” rating to a “sell” rating and set a $3.00 price target for the company. in a report on Monday, October 9th.
A number of hedge funds have recently added to or reduced their stakes in KDMN. Sphera Funds Management LTD. acquired a new stake in Kadmon during the 3rd quarter valued at $3,685,000. Vanguard Group Inc. increased its holdings in Kadmon by 166.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,508,869 shares of the company’s stock valued at $5,870,000 after purchasing an additional 941,549 shares in the last quarter. Crestline Management LP acquired a new stake in Kadmon during the 3rd quarter valued at $2,011,000. Sabby Management LLC acquired a new stake in Kadmon during the 2nd quarter valued at $2,112,000. Finally, Susquehanna International Group LLP increased its holdings in Kadmon by 3,211.2% during the 3rd quarter. Susquehanna International Group LLP now owns 443,135 shares of the company’s stock valued at $1,485,000 after purchasing an additional 429,752 shares in the last quarter. 51.90% of the stock is owned by hedge funds and other institutional investors.
Kadmon (NYSE:KDMN) last posted its earnings results on Thursday, November 9th. The company reported ($0.42) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.04). The company had revenue of $2.28 million during the quarter, compared to analyst estimates of $5.69 million. Kadmon’s revenue for the quarter was down 60.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($4.24) EPS. sell-side analysts anticipate that Kadmon will post -1.62 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Kadmon Holdings Inc (KDMN) Receives Average Recommendation of “Hold” from Analysts” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/02/kadmon-holdings-inc-kdmn-receives-average-recommendation-of-hold-from-analysts.html.
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.